“This isn't simply a cancer story. It's an equity story,” said Meredith Cummins, CEO of NeuroEndocrine Cancer Australia. “Where you live, how far you are from specialist care, and your socioeconomic circumstances are increasingly influencing outcomes for people diagnosed with neuroendocrine cancer.” …
Widening inequality threatens outcomes for Australians with neuroendocrine cancer
July 14, 2026 Latest News
Latest Video
New Stories
-
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News -
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - - Latest News -
Funding for new chemotherapy-free immunotherapy combination for follicular lymphoma
August 3, 2026 - - Latest News -
Listing offers treatment option for Australians with tumour induced osteomalacia
August 3, 2026 - - Latest News